Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  AIDS (London)

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.aids.0000163948.62176.e7PMID 11919483
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Response to treatment of chronic hepatitis C with interferon α in patients infected with HIV-1 is associated with higher CD4+ cell count

  2007cited by this paper
• Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users

  2004influential reference
• Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.

  2003cited by this paper
• Increasing Impact of Chronic Viral Hepatitis on Hospital Admissions and Mortality among HIV-Infected Patients

  2001cited by this paper
• Paroxetine for the prevention of depression induced by high-dose interferon alfa.

  2001cited by this paper
• Paroxetine for the prevention of depression induced by interferon alfa.

  2001cited by this paper
• Sharing of drug preparation equipment as a risk factor for hepatitis C.

  2001cited by this paper
• Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus–infected patients with congenital coagulation disorders

  2001cited by this paper
• Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus.

  2001cited by this paper
• Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus.

  2001cited by this paper
• Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection.

  2001cited by this paper
• Public health and changes in illicit drug prices.

  2001cited by this paper
• HIV-1 progression in hepatitis-C-infected drug users.

  2001cited by this paper
• Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: a case–control study

  2001cited by this paper
• Letters of condolence.

  2001cited by this paper
• Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.

  2001cited by this paper
• Combination of interferon induction therapy and ribavirin in chronic hepatitis C

  2001cited by this paper
• Infection with GB virus C and reduced mortality among HIV-infected patients.

  2001cited by this paper
• Treatment of chronic hepatitis C in active drug users.

  2001cited by this paper
• Effect of coinfection with GB virus C on survival among patients with HIV infection.

  2001cited by this paper
• Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin

  2001cited by this paper
• Treatment of acute hepatitis C with interferon alfa-2b.

  2001cited by this paper
• Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997.

  2001cited by this paper
• Long-term ef®cacy of combination therapy with interferon-á2b and ribavirin for severe chronic hepatitis C in HIV-infected patients

  2001cited by this paper
• Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C

  2001cited by this paper
• Long-term efficacy of combination therapy with interferon-α2b and ribavirin for severe chronic hepatitis C in HIV-infected patients

  2001cited by this paper
• Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

  2001cited by this paper
• Hepatitis C: a hepatologist's approach to an infectious disease.

  2001cited by this paper
• Mitochondrial toxic effects and ribavirin.

  2001cited by this paper
• Factors affecting liver fibrosis in human immunodeficiency virus–and hepatitis C virus–coinfected patients: Impact of protease inhibitor therapy

  2001cited by this paper
• Hepatitis C virus infection.

  2001cited by this paper
• Risk Factors for Severe Hepatic Injury After Introduction of Highly Active Antiretroviral Therapy

  2001cited by this paper
• Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis.

  2001cited by this paper
• Mitochondrial toxic effects and ribavirin.

  2001cited by this paper
• Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection.

  2001cited by this paper
• Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

  2001cited by this paper
• Chronic hepatitis C in HIV-coinfected patients: feasibility and efficacy of interferon-alpha2b and ribavirin combination therapy.

  2001cited by this paper
• Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients.

  2000cited by this paper
• Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

  2000cited by this paper
• Long-term Prognosis of Hepatitis C Virus Infection.

  2000cited by this paper
• Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.

  2000cited by this paper
• PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS

  2000cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.

  2000cited by this paper
• Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.

  2000cited by this paper
• Hepatitis C virus/human immunodeficiency virus coinfection: clinical management issues.

  2000cited by this paper
• Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report

  2000cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C.

  2000cited by this paper
• Population Pharmacokinetic and Pharmacodynamic Analysis of Ribavirin in Patients With Chronic Hepatitis C

  2000cited by this paper
• Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients

  2000cited by this paper
• Is an “à la carte” combination interferon alfa‐2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?

  2000cited by this paper
• Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues.

  2000cited by this paper
• Response-adjusted alpha-interferon therapy for chronic hepatitis C in HIV-infected patients.

  2000cited by this paper
• Mortality for liver disease in patients with HIV infection: a cohort study.

  2000influential reference
• Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus.

  2000cited by this paper
• Aggressive daily interferon therapy in HIV-HCV coinfected patients.

  2000cited by this paper
• The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985

  2000cited by this paper
• Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy

  2000cited by this paper
• Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy.

  2000cited by this paper
• Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy.

  2000influential reference
• Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment.

  2000cited by this paper
• Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study. French Multicenter Study Group.

  2000cited by this paper
• The natural history of hepatitis C virus infection: host, viral, and environmental factors.

  2000cited by this paper
• Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection.

  1999cited by this paper
• EASL International Consensus Conference on Hepatitis C

  1999cited by this paper
• [Interactions of antiretroviral drugs].

  1999cited by this paper
• Interferon plus ribavirin for chronic hepatitis C.

  1999cited by this paper
• Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma.

  1999influential reference
• Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy.

  1999cited by this paper
• Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection.

  1999cited by this paper
• Hepatitis C and HIV infection: biological, clinical, and therapeutic implications.

  1999cited by this paper
• Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients

  1999cited by this paper
• Interferon plus ribavirin in HIV-infected patients with chronic hepatitis C.

  1999cited by this paper
• Management of chronic hepatitis C in HIV-infected patients.

  1999cited by this paper
• Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA).

  1999cited by this paper
• Severe anoxic hepatic necrosis in an HIV-1-hepatitis C virus-co-infected patient starting antiretroviral triple combination therapy.

  1998cited by this paper
• Nevirapine-induced hepatitis treated with corticosteroids?

  1998cited by this paper
• Hepatitis C virus‐associated hepatitis following treatment of HIV‐infected patients with HIV protease inhibitors: an immune restoration disease?

  1998cited by this paper
• Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs.

  1998cited by this paper
• Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV.

  1998cited by this paper
• Hepatotoxicity after introduction of highly active antiretroviral therapy.

  1998cited by this paper
• Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy.

  1998cited by this paper
• Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy.

  1998cited by this paper
• Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

  1998cited by this paper
• Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. The Hepatitis/HIV Spanish Study Group.

  1997cited by this paper
• Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation.

  1997cited by this paper
• Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis.

  1997cited by this paper
• Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report.

  1997cited by this paper
• A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients. The Hepatitis/HIV Spanish Study Group.

  1997cited by this paper
• A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.

  1996cited by this paper
• Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV.

  1996cited by this paper
• Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group.

  1996cited by this paper
• High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV

  1995cited by this paper
• Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired Hepatitis C

  1995cited by this paper
• Impact of Immunosuppression Caused by HIV Infection on the Replication of Hepatitis C Virus

  1995cited by this paper
• Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy.

  1995cited by this paper
• Volunteer Blood Donors with Antibody to Hepatitis C Virus: Clinical, Biochemical, Virologic, and Histologic Features

  1995cited by this paper
• The progression of HCV‐associated liver disease in a cohort of haemophilic patients

  1994cited by this paper
• CD4+ T-lymphocytopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C. HIV-Hepatitis Spanish Study Group.

  1994cited by this paper
• Hepatitis C virus (HCV) viremia in human immunodeficiency virus-seronegative and -seropositive patients with indeterminate HCV recombinant immunoblot assay.

  1994cited by this paper
• Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients.

  1993cited by this paper

• Seroprevalence and Risk Factors of Hepatitis B and C Co-infection and Their Correlation with CD4 Cells and Liver Enzymes in HIV Patients at a Teaching Hospital in Nigeria

  2024cites this paper
• Immunogenicity and Efficacy of Vaccination in People Living with Human Immunodeficiency Virus

  2023cites this paper
• An integrated in-silico Pharmaco-BioInformatics approaches to identify synergistic effects of COVID-19 to HIV patients

  2023cites this paper
• Factors Associated with Liver Enzyme Abnormalities in HIV–HBV and/or HCV Co-infected Patients in Kinshasa, Democratic Republic of the Congo: Multicenter Cross-sectional Study

  2022cites this paper
• Evaluation of miRNA-122, miRNA-149, miRNA-199a, and miRNA- let7 Expression in HIV, HBV, and HIV-HBV Co-infected Patients

  2022cites this paper
• Factors Associated With Hepatic Cytolysis in HIV-HBV and/or HCV Coinfected Patients in Kinshasa, Democratic Republic Of The Congo: Multicenter Cross-Sectional Study

  2022cites this paper
• Three vs Four Dose Schedule of Double Strength Recombinant Hepatitis-B Vaccine in HIV-infected Children: A Randomized Controlled Trial

  2021cites this paper
• Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?

  2020cites this paper
• Experience with Hepatitis B Viral load Testing in Jharkhand

  2019cites this paper
• CD4+T- Lymphocytes And Alanine Aminotransferases of HIV Positive Patients Co-Infected With Hepatitis B Virus As Seen At The University Of Abuja Teaching Hospital: A 10 Year Retrospective Study

  2019cites this paper
• Management of HCV-Related Liver Disease in Hemophilia and Thalassemia

  2018cites this paper
• BURDEN OF CYTOPAENIAS AMONG HIV POSITIVE PREGNANT WOMEN AT THE UNIVERSITY COLLEGE HOSPITAL, IBADAN

  2018cites this paper
• Aspects of Coinfection With HIV and Hepatitis C Virus

  2017cites this paper
• Effets de l'anémie maternelle et ses causes sur le développement cognitif des enfants agés de 1 an au Bénin

  2016cites this paper
• Pharmacoeconomic modelling for policy decision-making : the case of sofosbuvir for hepatitis C infection in South Africa

  2016cites this paper
• Seroprevalence of HIV, HBV, HCV, and HTLV among Pregnant Women in Southwestern Nigeria

  2016cites this paper
• Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature

  2016cites this paper
• PhD thesis Non-HIV determinants of outcome in Danish HIV-infected patients: Impact of study participation, body fat distribution and family-related factors

  2015cites this paper
• Mexican consensus on the diagnosis and management of hepatitis C infection.

  2015cites this paper
• Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015.

  2015cites this paper
• Management of Chronic Hepatitis in Special Hosts and Special Situations: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases

  2015cites this paper
• SEROPREVALENCE OF HEPATITIS B ( HBS AG ) AND HEPATITIS C ( ANTI-HCV ) VIRUSES AMONG SUDANESE PATIENTS WITH HIV / TB CO-INFECTION 1

  2015cites this paper
• Adherence to highly active antiretroviral therapy impact on clinical and economic outcomes for Medicaid enrollees with human immunodeficiency virus and hepatitis C coinfection

  2015cites this paper
• Hepatitis B and C Seropositivity In A Cohort of HIV-Positive Patients In Ilorin, North-Central Nigeria

  2015cites this paper
• Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin

  2015cites this paper
• Impact of methamphetamine on infection and immunity

  2015cites this paper
• Cost‐effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection

  2014cites this paper
• German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients

  2014cites this paper
• Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.

  2014cites this paper
• A Review of the Natural History of Chronic Hepatitis C Infection

  2014cites this paper
• Prevalence and correlates of cytopenias in HIV-infected adults initiating highly active antiretroviral therapy in Uganda

  2014cites this paper
• Occurrence and spatial distribution of hepatitis C in a Western Brazilian Amazon state.

  2014cites this paper
• Human immunodeficiency virus and hepatitis C virus coinfection in Nepal

  2014cites this paper
• Valor predictivo de la elastometría hepática transitoria en el seguimiento de pacientes coinfectados VIH/VHC

  2014cites this paper
• Alcohol Use Disorders And Antiretroviral Therapy Among Prisoners With Hiv/aids In Argentina

  2014cites this paper
• Coinfection of Hepatitis B and C virus among HIV Patients Visiting Specialist Hospital in Ikole Ekiti, Nigeria

  2014cites this paper
• Human immunodeficiency virus type 1 Vpr increases hepatitis C virus RNA replication in cell culture.

  2014cites this paper
• Disparities and Risks of Sexually Transmissible Infections among Men Who Have Sex with Men in China: A Meta-Analysis and Data Synthesis

  2014cites this paper
• Human immunodeficiency virus and Hepatitis C virus co-infection in children in Jos, Nigeria

  2014cites this paper
• Predictors of Mortality among United States Veterans with Human Immunodeficiency Virus and Hepatitis C Virus Coinfection

  2014cites this paper
• Acoustic Radiation Force Impulse (ARFI) and Transient Elastography (TE) for evaluation of liver fibrosis in HIV-HCV co-infected patients

  2014cites this paper
• Hepatitis C virus treatment and survival in patients with hepatitis C and human immunodeficiency virus co‐infection and baseline anaemia

  2013cites this paper
• Hepatitis C Virus and HIV Type 1 Co-Infection

  2013cites this paper
• Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysis.

  2012cites this paper
• Challenges in the Management of HIV and Hepatitis C Virus Co-infection

  2012cites this paper
• Buprenorphine for Human Immunodeficiency Virus/Hepatitis C Virus–coinfected Patients: Does It Serve as a Bridge to Hepatitis C Virus Therapy?

  2012cites this paper
• The Influence of Treatment with Pegylated Interferon-Alfa and Ribavirin on Neutrophil Function and Death in Patients with HIV/HCV Coinfection

  2012cites this paper
• Influence of IL28B Polymorphisms on Response to a Lower-Than-Standard Dose peg-IFN-α 2a for Genotype 3 Chronic Hepatitis C in HIV-Coinfected Patients

  2012cites this paper
• Rapid diagnostic HCV antibody assays.

  2012cites this paper
• Eating patterns among heroin users: a qualitative study with implications for nutritional interventions.

  2012cites this paper
• The Cost of HIV Disease in Northern Italy: The Payer's Perspective

  2011cites this paper
• Genotypes and viral load of hepatitis C virus among persons attending a voluntary counseling and testing center in Ethiopia

  2011cites this paper
• An Interrupted Time Series Evaluation of a Hepatitis C Intervention for Persons with HIV

  2011cites this paper
• Commentary: A Call for Routine HIV Testing Among Patients with Hepatitis C Virus Infection

  2011cites this paper
• Hepatitis C Transmission, Prevention, and Treatment Knowledge Among Patients with HIV

  2010cites this paper
• Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus.

  2010cites this paper
• Comorbidities associated with the increasing burden of hepatitis C infection

  2010cites this paper
• Ten years later: A single hospital experience with malignancy in HIV/AIDS

  2010cites this paper
• Hepatitis C infection in HIV-1 natural viral suppressors

  2010cites this paper
• Provider Reports on the Ability to Implement Changes in Practice Following HIV-HCV Training

  2010cites this paper
• Validation of Biochemical Markers for the Prediction of Liver Fibrosis and Necroinflammatory Activity in Hemodialysis Patients with Chronic Hepatitis C

  2010cites this paper
• Factors associated with the progression of hepatic fibrosis in end-stage kidney disease patients with hepatitis C virus infection

  2009cites this paper
• Adherencia y aspectos psicológicos en pacientes adultos infectados por el VIH con prolongada exposición a tratamiento antirretroviral

  2009cites this paper
• [Alpha-interferon versus peg-interferon associated to ribavirin in the treatment of genotype 1 hepatitis C virus and human immunodeficiency virus coinfected patients].

  2009cites this paper
• The pathogenesis of liver disease in the setting of HIV–hepatitis B virus coinfection

  2009cites this paper
• Nutrition Issues in Chronic Drug Users Living With HIV Infection

  2009cites this paper
• Peginterferon Plus Ribavirin for Chronic Hepatitis C in Patients With Human Immunodeficiency Virus

  2009cites this paper
• Hepatitis B and C virus co-infection in Nigerian patients with HIV infection.

  2009cites this paper
• Human immunodeficiency virus and hepatitis C virus co-infection: epidemiology, natural history and the situation in China.

  2009cites this paper
• [HIV/HCV coinfection at an university hospital in Recife, Brazil].

  2009cites this paper
• Identification of novel markers for liver fibrosis in HIV/hepatitis C virus coinfected individuals using genomics-based approach

  2008cites this paper
• Methamphetamine enhances Hepatitis C virus replication in human hepatocytes

  2008cites this paper
• Role of rapid virological response in prediction of sustained virological response to Peg‐IFN plus ribavirin in HCV /  HIV co‐infected individuals

  2008cites this paper
• Neuropsychiatric aspects of coinfection with HIV and hepatitis C virus.

  2008cites this paper
• The influence of HCV coinfection on clinical, immunological and virological responses to HAART in HIV-patients.

  2008cites this paper
• Clinical management of HIV/hepatitis C virus coinfection

  2008cites this paper
• Non-AIDS-defining cancers: should antiretroviral therapy be initiated earlier?

  2008cites this paper
• Interferon-Based Therapy for HCV in People with HCV / HIV Coinfection

  2008cites this paper
• Antiretroviral drugs and liver injury.

  2008cites this paper
• Hepatitis C Virus (HCV): A Review of Immunological Aspects

  2008cites this paper
• Efficacy and Safety of Adefovir Dipivoxil plus Pegylated Interferon-α2a for the Treatment of Lamivudine-Resistant Hepatitis B virus Infection in HIV-Infected Patients

  2008cites this paper
• Management of chronic hepatitis C virus infection in HIV-infected patients.

  2008cites this paper
• Impact and management of hepatitis B and hepatitis C virus co-infection in HIV patients.

  2008cites this paper
• Measurement of Ribavirin Plasma Concentrations by High-performance Liquid Chromatography Using a Novel Solid-phase Extraction Method in Patients Treated for Chronic Hepatitis C

  2007cites this paper
• Enhanced and resumed GB virus C replication in HIV-1-infected individuals receiving HAART

  2007cites this paper
• Predictors of Clinical Progression among HIV-1–Positive Patients starting HAART with CD4+ T-cell Counts ≥200 cells/mm3

  2007cites this paper
• The treatment of chronic hepatitis C in HIV‐infected patients: a meta‐analysis

  2007cites this paper
• HIV/HCV co‐infection: histopathologic findings, natural history, fibrosis, and impact of antiretroviral treatment: a review article

  2007influential citation
• There is no difference in hepatic fibrosis rates of patients infected with hepatitis C virus and those co-infected with HIV.

  2007cites this paper
• Impact of human immunodeficiency virus infection in patients infected with the hepatitis C virus

  2007cites this paper
• Should we now adopt the HIV-RNA < 50 copy endpoint for clinical trials of antiretroviral-experienced as well as naive patients?

  2007cites this paper
• Prevalence of and Factors Associated With Hepatic Steatosis in Patients Coinfected With Hepatitis C Virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine Cohort

  2007cites this paper
• Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.

  2007cites this paper
• Killer immunoglobulin-like receptor genotype may distinguish immunodeficient HIV-infected patients resistant to immune restoration diseases associated with herpes virus infections.

  2007influential citation
• Recognition of hepatitis C virus coinfection in HIV-positive injecting drug users in Asia.

  2007cites this paper
• Therapeutic issues in HIV/HCV-coinfected patients

  2007cites this paper
• Foie et antirétroviraux : hépatotoxicité, stéatose et monitoring en cas d'hépatopathie

  2007cites this paper
• Chronic coinfection with hepatitis B and hepatitis C viruses in an Italian population of HIV-infected patients.

  2007cites this paper
• [Liver and antiretrovirals: hepatotoxicity, steatosis and monitoring of patients with liver disease].

  2007cites this paper
• Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV‐coinfected patients

  2007cites this paper